# TABLE OF CONTENTS

**OPENING REMARKS**

Dr D. H. Calam, Chair of the European Pharmacopoeia Commission

**SESSION I: LOOKING BACK AT 4 YEARS' PHARMACOPOEIAL WORK:**

**Recent Changes in the European Pharmacopoeia**

Mr P. Castle, Secretary to the European Pharmacopoeia Commission

Dr D. H. Calam, Chair of the European Pharmacopoeia Commission

**Experience and practical viewpoint of an OMCL**

Dr M. Wierer, Landesinstitut für den öffentlichen Gesundheitsdients Nordrhein-Westfalen Arneimitteluntersuchungsstelle (Münster - Germany)

**Discussion Session I**

**SESSION II: SETTING CONTENT LIMIT / ACCEPTANCE OF ANALYTICAL RESULTS:**

**Challenging the principles of setting limits in pharmacopoeial tests**

Prof. S. H. Hansen, Royal Danish School of Pharmacy, Department of Analytical & Pharmaceutical Chemistry (Copenhagen - Denmark)

**Limits for setting limits**

Dr M.Weber, EMPA (St Gallen - Switzerland)

**How to set up specifications for new chemical entities during preclinical and clinical phases**

Mr M. Bauer, Sanofi Synthelabo Centre de Recherche, Départment International d'Analyses (Toulouse - France)

**Discussion Session II**

**TOPIC 1: USE, ESTABLISHMENT AND ASSIGNED VALUE OF REFERENCE SUBSTANCES**

**Use of reference substances in the analytical control laboratory:**

**Needs for innovative pharmaceutical industry**

Dr A. Brutsche, Novartis Pharma, (Stein - Switzerland)

**Needs for generic pharmaceutical industry**

Dr A. Rotar, KRKA d.d., (Novo Mesto - Slovenia)

**Needs for regulation and inspection**

Dr G. Lee, Medicines Control Agency (MCA), (London - Great Britain)

**Discussion**

**Present Policy of the European Pharmacopoiea for the different categories concerned:**

**Chemical Reference Substances (CRS):**

**Role of the EDQM in organising collaborative studies/assigned value/uncertainty**

Dr J. Miller, Head of Laboratory, EDQM (Strasbourg – France)

**Standards - the key to effective analytical measurement performance**

Dr K. J. Leiper, Benson Associates (Grantham - Great Britain)

**Discussion**

**Establishment of the reference material: How to elaborate a CRS?**

**Role of the industry in the establishment of a CRS**

Mr J. van Rompay, Janssen Research Foundation, (Beerse-Belgium)

**Role and responsibilities of an OMCL in establishing reference substances: Background and practical experience from the participation**

Dr P. Helboe, Danish Medicines Agency (DKMA), (Copenhagen-Denmark)

**Discussion**

**CRS impurities. When? How?**

Dr F. Erni, Novartis Pharma, (Basel - Switzerland)

**General Discussion:**

**TOPIC 2: NEW AND EMERGING TECHNIQUES**

**Advanced chromatograhic and electrophoretic methods for testing enantiomeric purity**

Prof. Dr G. Blaschke, Institute of Pharmaceutical Chemistry (Münster - Germany)

**General aspects of the near infrared spectrometry technique. Validation and comparison with traditional wet chemistry of the Ph. Eur. methods**

Mr A. C. M. Gerich, Organon NV, (Oss - The Netherlands)

**Using near infrared spectrometry in an OMCL**

Dr D. De Kaste, National Institute for Public Health and the Environment (RIVM), (Bilthoven - The Netherlands)

**Raman spectrometry - an emerging technique with exciting possibilities**

Dr C. E. Sjøgren, Nycomed Amersham Imaging AS, (Oslo- Norway)

**Liquid Chromatography – Mass Spectrometry for identification of drug impurities**

Dr L. Tollsten, AstraZeneca R&D, (Mölndal – Sweden)

**In process control versus testing the finished product**

Prof. C. Graffner, Medical Products Agency, (Uppsala - Sweden)

**Towards parametric release in pharmaceutical production: Process analytical chemistry paves the way**

Prof. S. Folestad, AstraZeneca R&D, (Mölndal - Sweden)

**The practical applications of the Ph. Eur. excipient monographs in the industry? 61**

Dr V. Bühler, BASF AG (Ludwigshaffen - Germany)

**New excipients and new methods to characterise excipients**

Prof. H. J. De Jong, Institut de Recherches Internationales Servier and IPEC-Europe

**Discussion**

**SESSION III: SEPARATION TECHNIQUES**

**Latest developments of general separation methods**

Prof. Dr S. Ebel, Department of Pharmacy, University(Würzbürg - Germany)

**Process vs. Performance control in HPLC; Characterisation of columns and instrumentation**

Prof. Dr H. Engelhardt, Universität des Saarlandes, (Saarbrücken - Germany)

**Adjustment of chromatographic conditions/ permitted variability**

Dr G. Houghton, Medicines Control Agency (MCA), (London - Great Britain)

**System performance and variability of chromatographic techniques used in pharmaceutical quality control**

Dr B. Renger, Byk Gulden, (Konstanz - Germany)

**Equipment qualification and revalidation of analytical procedure**

Dr J. Ermer, Aventis Pharma, (Frankfurt - Germany)

**Are presently prescribed system suitability requirements sufficient?**

Prof. Dr J. Hoogmartens, Katholieke Universiteit Leuven, (Leuven - Belgium)

**Round table discussion**

**SESSION IV: PROSPECTIVE AND EXPECTATIONS**

**Inorganic impurities in pharmaceutical preparations/ origin, relevance, and consequences for pharmacopoieal monographs**

Dr D. Jäkel, Novartis Pharma (Stein - Switzerland)

**Control of medicines: link between registration authorities OMCL's and Pharmacopoeias**

Dr J. L. Robert, OMCL and Chair Joint CPMP/CVMP Quality Working Party (EMEA)

**Round table discussion: Prospective and expectations from the users**

**Biographical notes**

**Final List of Participants**